Frontlight ResearchEarly access
Myeloproliferative neoplasms trials in Uzbekistan
1 trial · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleStudy of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic Disorders
- Where
- Tashkent
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Eilean Therapeutics
See details and how to joinNCT07529951